Posted in BCBS Empire NY, NY Providers, Pharmacy (Various Insurance Payers), Training, Updates

BCBS (NY): HIV medication combinations may require Prior Auth, 05/01/2021

Effective 05/01/21 and for the DOS thereafter, BCBS (Empire) NY, will implement a new prior authorization for HIV medications/drugs. This would help to ensure that the patients are not receiving therapeutic duplications when taking certain combinations.

In order for the Member to continue to receive the treatment that involves drug combinations, the provider must submit an authorization for EACH Drug and provide a MEDICAL NECESSITY rationale as to why that drug combination is clinically needed.

Combinations that are considered clinical duplicates are based on drug mechanism of action (MOA) and developed in accordance with the U.S. Department of Health and Human Services HIV Guidelines.

Examples of HIV drug combinations that would trigger duplicated drug combinations:

Providers and members expected to be impacted by this policy will receive advanced notice by mail.

Source: BCBS (NY) Providers Communications: March 2021

Posted in #unitedhealthcare, Pharmacy (Various Insurance Payers), Training, Updates

UHC (NY) Commercial and Community Health Pharmacy update: Xiaflex®, Riabni (rituximabarrx) for 2021

UHC Commercial Plan:

Xiaflex® Apr. 1, 2021- Treatment of Dupuytren’s contracture:

Changes:
• Adding notification/prior
authorization requirement
• Adding Admin Guide
Medication Sourcing
requirement (additional
information below)

Administrative Guide Medication Sourcing Requirement for Xiaflex – Apr. 1, 2021
As a reminder, the 2021 Care Provider Administrative Guide includes information on medication sourcing requirements for in-network providers. The sourcing requirement for some specialty medications apply to all outpatient care providers (referred to as Medication Sourcing), while other sourcing requirements only apply to outpatient hospital providers (referred to as Medication Sourcing Expansion). Xiaflex will be placed under Medication Sourcing Program that applies to all outpatient care providers, effective Apr. 1, 2021. UHC have contracted specialty pharmacies for the distribution of these specialty medications. UHC participating specialty pharmacy providers give fulfillment
and distribution services to meet the needs of UHC members and UHC care providers. Effective Apr. 1, 2021, you must acquire Xiaflex from US Bioservices, unless otherwise authorized by us. The requirement does not apply when Medicare or another health benefit plan is the primary payer and UHC is the secondary payer. Contact your local UnitedHealthcare network management representative if you have any questions.

UHC Community Health:

Riabni™(rituximabarrx)Jun. 1, 2021 – Rituximab is for the treatment of several
cancer and non-cancer related conditions, including: immune thrombocytopenic purpura,
pemphigus vulgaris, Wegener’s granulomatosisrheumatoid arthritis.

Changes:
• Adding notification/prior
authorization requirement
• Preferred products:
Ruxience® and Truxima®;
Rituxan®, Rituxan Hycela®
and Riabni™ will be nonpreferred.

Source: UHC March Provider News.

Posted in BCBS Empire NY, Pharmacy (Various Insurance Payers), Training, Updates

Empire BCBS (NY) Specialty Pharmacy Changes updates for 2021

Reminder #1:

  1. Empire BlueCross BlueShield’s (“Empire”) pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by Empire’s medical specialty drug review team.
  2. Oncology drugs will be managed by AIM Specialty Health (AIM), a separate company.

New Clinical Criteria effective December 22, 2020

The following clinical criteria is new.

  • ING-CC-0184 Danyelza (naxitamab-gqgk)

New Clinical Criteria effective June 1, 2021

The following clinical criteria is new.

  • ING-CC-0185 Oxlumo (lumasiran)

Revised Clinical Criteria Effective 12/22/2020:

The following current clinical criteria were revised to expand medical necessity indications or criteria.

  • ING-CC-0124 Keytruda (pembrolizumab)

Revised Clinical Criteria effective January 25, 2021

The following current clinical criteria were revised to expand medical necessity indications or criteria.

  • ING-CC-0002 Colony Stimulating Factor Agents
  • ING-CC-0015 Infertility and HCG Agents
  • ING-CC-0032 Botulinum Toxin
  • ING-CC-0154 Givlaari (givosiran)

Revised Clinical Criteria effective January 25, 2021

The following clinical criteria were reviewed with no significant change to the medical necessity indications or criteria.

  • ING-CC-0079 Strensiq (Asfotase Alfa)
  • ING-CC-0177 Zilretta (triamcinolone acetonide extended-release)

Revised Clinical Criteria effective June 1, 2021

The following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

  • ING-CC-0032 Botulinum Toxin
  • ING-CC-0154 Givlaari (givosiran)

Reminder #2:

Effective June 12, 2021, Empire BCBS NY will be implementing coding updates in the claims system for the following clinical criteria listed below which may result in not medically necessary determinations for certain services.

  • ING-CC-0066 Monoclonal Antibodies to Interleukin-6

To view the complete policies, please visit the following links:

  1. Danyelza
  2. Oxlumo
  3. Keytruda
  4. Colony Stimulating Factor Agents
  5. Infertility and HCG Agents
  6. Botulinum Toxin
  7. Givlaari
  8. Strensiq
  9. Zilretta